CTX — Crescita Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$8.21m
- CA$0.08m
- CA$17.52m
- 77
- 84
- 11
- 58
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1.85 | 0.037 | -1.1 | 0.862 | -1.99 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.409 | 2.43 | 0.778 | 0.82 | 0.494 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.012 | 1.17 | -2.75 | -3.71 | 1.61 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | 5.31 | 5.61 | -1.6 | -1.02 | 2.08 |
Capital Expenditures | -0.215 | -0.059 | -0.346 | -0.229 | -0.133 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -0.5 | -0.061 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.215 | -0.059 | -0.846 | -0.29 | -0.133 |
Financing Cash Flow Items | -0.25 | -0.05 | -0.05 | -0.05 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -4.39 | -0.476 | -0.5 | -1.85 | -0.782 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.679 | 5.01 | -2.95 | -3.09 | 1.15 |